<DOC>
	<DOC>NCT01656395</DOC>
	<brief_summary>The purpose of this adaptive-design study is to evaluate the dose-related effectiveness and safety of MK-1029, alone or in combination with montelukast, compared to placebo and to montelukast alone, in the treatment of persistent asthma in adults.</brief_summary>
	<brief_title>A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>not pregnant or breastfeeding, and not planning to become pregnant during the study history of symptoms of persistent asthma for at least one year current use of acceptable asthma treatments and willingness to taper or discontinue these treatments; acceptable asthma treatments: use of inhaled SABAs (e.g., albuterol/salbutamol) only "asneeded" with no use of asthma controller medications; OR use of stable doses of low or mediumdose inhaled corticosteroids (ICS), alone, or in combination with either a longacting betaagonist (LABA) or other asthma controller medications (including leukotriene receptor antagonists) and can tolerate tapering or discontinuation no history of smoking OR no smoking within &lt;1 year with a smoking history of ≤10 packyears ability to maintain a constant day/night, awake/sleep cycle agreement to not change habitual consumption of beverages or food containing caffeine throughout the study Body Mass Index (BMI) of 15 to 40 kg/m^2 myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within past ≤3 months hospitalization within past ≤4 weeks major surgical procedure within past ≤4 weeks participation in a clinical study involving an investigational drug within past ≤4 weeks current regular use or recent (within past ≤5 years) past abuse of alcohol (&gt;14 drinks/week) or illicit drugs donation of a unit of blood within past ≤2 weeks or intention to donate a unit of blood during the study evidence of another clinically significant, active pulmonary disorder such as chronic obstructive pulmonary disease (COPD) emergency room treatment for asthma within past ≤4 weeks or hospitalization for asthma within past ≤8 weeks respiratory tract infection requiring antibiotic treatment within past ≤8 weeks evidence of active, clinically significant sinus disease within past ≤1 week history of a clinically significant psychiatric disorder, other than stable depression, within past ≤12 weeks history of HIV hypersensitivity or intolerance to inhaled betaagonists, leukotriene antagonists, leukotriene synthesis inhibitors, or any of their ingredients, including lactose and galactose clinically unstable disease of the ophthalmologic, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic systems current cancer or history (within past ≤5 years) of cancer (except for successfully treated basal and squamous cell carcinomas of the skin); if cancerfree for &gt;5 years, study participation may be allowed evidence of uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>